Compare DUO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | AKTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.5M |
| IPO Year | 2018 | 2014 |
| Metric | DUO | AKTX |
|---|---|---|
| Price | $1.37 | $6.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | ★ 66.7K | 17.9K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.12 |
| 52 Week High | $5.34 | $6.59 |
| Indicator | DUO | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 65.71 |
| Support Level | $1.30 | $0.27 |
| Resistance Level | $1.52 | $6.46 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 8.35 | 74.68 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.